| Author: | Kan, Chau Ming |
| Title: | Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer |
| Advisors: | Wong, Sze-chuen Cesar (HTI) |
| Degree: | DHSc |
| Year: | 2023 |
| Subject: | RNA Blood plasma Tumor markersBiochemical markers Colon (Anatomy) -- Cancer Rectum -- Cancer -- Diagnosis Hong Kong Polytechnic University -- Dissertations |
| Department: | Faculty of Health and Social Sciences |
| Pages: | iii, 98 pages : color illustrations |
| Language: | English |
| Abstract: | Colorectal cancer (CRC) is one of the top three causes of cancer death in the world. In spite of improved treatments and screening programs, 16.6% - 30% of CRC sufferers will experience a recurrence after 4.4 years following curative surgery. The use of cell-free RNA (cfRNA) has gained popularity in clinical fields such as cancer detection because it contains fragments of transcripts from various types of cells. There is, however, a lack of understanding regarding the pathophysiology behind cfRNAs present in the plasma of patients with CRC. Using published single-cell transcriptomics profiles, we deconvoluted paired plasma samples collected from CRC patients who underwent tumor-ablative surgery to establish the tissue-specific contributions of cfRNAs transcriptomic profiles. Transcriptomic components from intestinal secretory cells were significantly reduced in the in-house post-operative cfRNA, suggesting that cfRNAs originated from CRC. Further validation of differentially expressed cfRNAs was conducted with CRC tumor samples and tumor-adjacent samples from 8 patients with CRC. According to our studies, HPGD, PACS1 and TDP2 showed consistent differential expression between cfRNAs and CRC tissues, which suggests they may be tumor-derived. Our results were further confirmed by analyzing the Cancer Genome Atlas (TCGA) colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) datasets, and we were able to separate the patients into two groups based on their survival outcomes. The three-gene signature (HPGD, PACS1 and TDP2) may be applicable to minimal residual disease (MRD) testing, which is used to examine cancer cells remaining after treatment. |
| Rights: | All rights reserved |
| Access: | restricted access |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 7288.pdf | For All Users (off-campus access for PolyU Staff & Students only) | 3.83 MB | Adobe PDF | View/Open |
Copyright Undertaking
As a bona fide Library user, I declare that:
- I will abide by the rules and legal ordinances governing copyright regarding the use of the Database.
- I will use the Database for the purpose of my research or private study only and not for circulation or further reproduction or any other purpose.
- I agree to indemnify and hold the University harmless from and against any loss, damage, cost, liability or expenses arising from copyright infringement or unauthorized usage.
By downloading any item(s) listed above, you acknowledge that you have read and understood the copyright undertaking as stated above, and agree to be bound by all of its terms.
Please use this identifier to cite or link to this item:
https://theses.lib.polyu.edu.hk/handle/200/12838